10 Best Gene Therapy Stocks to Buy Right Now

3) Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Number of Hedge Fund Holders: 30

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a genome editing company, which continues to focus on the development of curative therapeutics.

Intellia Therapeutics, Inc. (NASDAQ:NTLA) continues to make strides in treating conditions like hereditary angioedema (HAE) and transthyretin amyloidosis (ATTR), positioning itself as a potential disruptor in the gene editing space. HAE is a rare, genetic disorder characterized by unpredictable and debilitating swelling episodes. The current treatments for HAE focus on frequent injections or infusions to prevent attacks, which can be burdensome for patients.

NTLA-2002 provides a one-time, potentially curative solution by silencing the KLKB1 gene, which reduces kallikrein protein levels responsible for triggering HAE attacks. Furthermore, NTLA-2002’s potential as a single-dose therapy is expected to replace chronic, lifelong treatments. This transformative approach should capture a significant share of the HAE treatment market by addressing the root cause of the disease, providing sustained efficacy, and improving patient quality of life.

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s CRISPR technology and delivery system provide a healthy foundation for clinical success and market adoption.

In October, Intellia Therapeutics, Inc. (NASDAQ:NTLA) presented positive Phase 2 data from the ongoing Phase 1/2 study, with results continuing to support the potential of NTLA-2002 to be a functional cure for HAE. As per Coherent Market Insights, HAE market size is expected to touch US$5.36 billion by 2031, demonstrating a strong unmet opportunity for Intellia Therapeutics, Inc. (NASDAQ:NTLA).